Semler Scientific investors file class action lawsuit, deadline Oct. 28, 2025.
ByAinvest
Sunday, Sep 7, 2025 8:32 am ET1min read
SMLR--
The lawsuit alleges that Semler Scientific did not disclose a material investigation by the United States Department of Justice (DOJ) into violations of the False Claims Act. This failure to disclose led to investors suffering damages when the true details emerged [1]. The DOJ investigation was disclosed on February 28, 2025, resulting in a $4.03 drop in stock price, or a 9.4% decrease. On April 15, 2025, Semler announced a settlement with the DOJ for $29.75 million, leading to a further $3.40 drop in stock price, a 9.9% decrease [1].
Investors who purchased Semler securities during the Class Period have until October 28, 2025, to seek appointment as Lead Plaintiff in the lawsuit. This deadline is crucial as it allows investors to direct the litigation and potentially recover damages [1]. To participate or learn more about the class action, investors can contact Glancy Prongay & Murray LLP at 310-201-9150 or shareholders@glancylaw.com, or The Rosen Law Firm at 866-767-3653 or case@rosenlegal.com [1][2].
The Rosen Law Firm has a proven track record in securities class actions and has recovered hundreds of millions of dollars for investors. The firm has been ranked in the top 4 each year since 2013 and has achieved the largest ever securities class action settlement against a Chinese company [2].
Investors are encouraged to act promptly to protect their rights and potential compensation. For more information, visit https://rosenlegal.com/submit-form/?case_id=39889 or contact Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com.
References:
[1] https://www.morningstar.com/news/business-wire/20250905390183/deadline-alert-semler-scientific-inc-smlr-investors-who-lost-money-urged-to-contact-glancy-prongay-murray-llp-about-securities-fraud-lawsuit
[2] https://www.morningstar.com/news/pr-newswire/20250903dc64768/smlr-investors-have-opportunity-to-lead-semler-scientific-inc-securities-fraud-lawsuit-first-filed-by-the-rosen-law-firm
Semler Scientific, Inc. (NASDAQ: SMLR) has been sued for securities fraud by Rosen Law Firm on behalf of investors who bought the company's securities between March 10, 2021 and April 15, 2025. If you purchased Semler Scientific securities during this period, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. To join the class action, visit rosenlegal.com or call Phillip Kim, Esq. at 866-767-3653.
Semler Scientific, Inc. (NASDAQ: SMLR) is facing a class action lawsuit alleging securities fraud and unlawful business practices. The lawsuit, filed by The Rosen Law Firm on behalf of investors who purchased Semler securities between March 10, 2021, and April 15, 2025, claims that the company made materially false and misleading statements and failed to disclose significant adverse facts about its business and operations.The lawsuit alleges that Semler Scientific did not disclose a material investigation by the United States Department of Justice (DOJ) into violations of the False Claims Act. This failure to disclose led to investors suffering damages when the true details emerged [1]. The DOJ investigation was disclosed on February 28, 2025, resulting in a $4.03 drop in stock price, or a 9.4% decrease. On April 15, 2025, Semler announced a settlement with the DOJ for $29.75 million, leading to a further $3.40 drop in stock price, a 9.9% decrease [1].
Investors who purchased Semler securities during the Class Period have until October 28, 2025, to seek appointment as Lead Plaintiff in the lawsuit. This deadline is crucial as it allows investors to direct the litigation and potentially recover damages [1]. To participate or learn more about the class action, investors can contact Glancy Prongay & Murray LLP at 310-201-9150 or shareholders@glancylaw.com, or The Rosen Law Firm at 866-767-3653 or case@rosenlegal.com [1][2].
The Rosen Law Firm has a proven track record in securities class actions and has recovered hundreds of millions of dollars for investors. The firm has been ranked in the top 4 each year since 2013 and has achieved the largest ever securities class action settlement against a Chinese company [2].
Investors are encouraged to act promptly to protect their rights and potential compensation. For more information, visit https://rosenlegal.com/submit-form/?case_id=39889 or contact Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com.
References:
[1] https://www.morningstar.com/news/business-wire/20250905390183/deadline-alert-semler-scientific-inc-smlr-investors-who-lost-money-urged-to-contact-glancy-prongay-murray-llp-about-securities-fraud-lawsuit
[2] https://www.morningstar.com/news/pr-newswire/20250903dc64768/smlr-investors-have-opportunity-to-lead-semler-scientific-inc-securities-fraud-lawsuit-first-filed-by-the-rosen-law-firm
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet